Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2′-deoxyuridine after intravesical infusion in patients with bladder cancer

Journal of Nuclear Medicine

Volumn 37, Issue 4 SUPPL., 1996, Pages

  Mariani, Giuliano ^a   Collecchi, Paola ^b   Baldassarri, Sergio ^b   Di Luca, Lorella ^b   Buralli, Simona ^b   Fontanini, Gabriella ^b   Baranowska Kortylewicz, Janina ^b   Adelstein, S James ^b   Kassis, Amin I ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Bladder cancer; Intravesical instillation; Iodine 125 IUdR; Locoregional administration

Indexed keywords

IDOXURIDINE; RADIOACTIVE IODINE;

AGED; ARTICLE; BLADDER; BLADDER TUMOR; CELL CULTURE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; MITOSIS; PATHOLOGY; RADIATION EXPOSURE;

ADMINISTRATION, INTRAVESICAL; AGED; HUMANS; IDOXURIDINE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MITOSIS; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0030119258     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kantoff PW, Shipley WU, Gallagher J, Loughlin KR, Soto EA. Cancer of the bladder. In: Osteen RT, ed. Cancer manual, 8th edition. Boston: American Cancer Society; 1990:295-303.
2. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hemat Oncol Clin North Am 1992;6:1-30.
3. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics. CA Cancer J Clin 1994;44:7-26.
4. Sarosdy MF. Principles of intravesical chemotherapy and immunotherapy. Urol Clin North Am 1992;19:509-519.
5. Whitmore WF Jr. Bladder cancer: an overview. CA Cancer J Clin 1988;38:213-223.
6. Van den Abbeele AD, Barclay PD, Tutrone RF, et al. Diagnostic and therapeutic implications of radioiodinated IUdR [*IUdR] uptake in exfoliated cells obtained from patients with bladder cancer [Abstract]. J Nucl Med 1993;34(suppl):221P.
7. 125I]IUdR therapy [Abstract]. J Nucl Med 1994;35(suppl):144P.
8. Sufrin G, Meyer JS, Martin SA, Schechtman K. Proliferative activity of urothelium and tumors of renal pelvis, ureter, and urinary bladder evaluated by thymidine labeling. Urology 1984;23(suppl):15-22.
9. Kassis AI, Howell RW, Sastry KSR, Adelstein SJ. Positional effects of Auger decays in mammalian cells in culture. In: Baverstock KF, Charlton DE, eds. DNA damage by Auger emitters. London: Taylor & Francis; 1988:1-13.
10. 131I. Radiat Res 1971;47:94-109.
11. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987;109:78-89.
12. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 1977;265:620-621.
13. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991;21:1541-1551.
14. Kassis AI, Van den Abbeele AD, Wen PYC, et al. 5-[I-125]iodo-2′-deoxyuridine in the radiotherapy of solid brain tumors in rats [Abstract]. J Nucl Med 1993;34(suppl):241P.
15. 125IUdR in a rat model of meningeal carcinomatosis [Abstract]. Proc Am Assoc Cancer Res 1994;35;414.
16. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, et al. Radiolabeled iododeoxyuridine: safety evaluation. J Nucl Med 1996;37(suppl):13S-16S.
17. Mariani G, Cei A, Collecchi P, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med 1993;34:1175-1183.
18. 123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 1996;37(suppl):22S-25S.
19. 125I]iodo-2′-deoxyuridine injected intratumorally in patients with breast cancer. Ann NY Acad Sci 1993;698:204-211.